Wilkinson Global Asset Management LLC Sells 1,585 Shares of Zoetis Inc. (NYSE:ZTS)

Wilkinson Global Asset Management LLC reduced its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 117,104 shares of the company’s stock after selling 1,585 shares during the period. Zoetis comprises approximately 1.4% of Wilkinson Global Asset Management LLC’s portfolio, making the stock its 26th biggest holding. Wilkinson Global Asset Management LLC’s holdings in Zoetis were worth $22,880,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Geneos Wealth Management Inc. boosted its holdings in Zoetis by 15.4% during the 1st quarter. Geneos Wealth Management Inc. now owns 5,247 shares of the company’s stock valued at $888,000 after acquiring an additional 699 shares during the period. Advisory Alpha LLC boosted its position in Zoetis by 28.7% during the 1st quarter. Advisory Alpha LLC now owns 2,199 shares of the company’s stock valued at $372,000 after buying an additional 490 shares during the period. Manchester Capital Management LLC grew its holdings in Zoetis by 12.8% in the 1st quarter. Manchester Capital Management LLC now owns 2,246 shares of the company’s stock worth $380,000 after acquiring an additional 255 shares during the last quarter. Duality Advisers LP grew its stake in shares of Zoetis by 43.7% in the first quarter. Duality Advisers LP now owns 40,641 shares of the company’s stock worth $6,877,000 after purchasing an additional 12,359 shares during the last quarter. Finally, Empirical Finance LLC raised its position in Zoetis by 3.4% during the 1st quarter. Empirical Finance LLC now owns 16,757 shares of the company’s stock valued at $2,835,000 after purchasing an additional 554 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

NYSE ZTS opened at $170.37 on Thursday. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The stock has a 50-day moving average of $188.46 and a 200 day moving average of $179.17. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The company has a market capitalization of $77.19 billion, a price-to-earnings ratio of 32.02, a PEG ratio of 2.68 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 52.59%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.36 earnings per share. On average, sell-side analysts forecast that Zoetis Inc. will post 5.91 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 1.01%. Zoetis’s payout ratio is 32.33%.

Analysts Set New Price Targets

ZTS has been the topic of a number of research analyst reports. Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. boosted their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Stifel Nicolaus increased their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Finally, BTIG Research boosted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.